Clinical Trial Details

EORTC-26101-BTG

Back to Clinical Trials Database

Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma – (previously: Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma)

Study documentation Publications

Trial Status All trial activities ended
Dates Date of activation: 07-Oct-2011
Date Step1 close: 07-Jan-2015
Data management at EORTC Yes
Design Phase 3
Randomized open label
Targeted Sample size EORTC Groups: 592 - All Groups: 592
Treatment Drug, Drug
Bevacizumab, Lomustine
Study Staff Wolfgang Wick (Study Coordinator) , UniversitaetsKlinikum Heidelberg - Head Hospital, Heidelberg
Joana Brilhante (Imaging Officer) joana.brilhante (at) eortc.org, EORTC Headquarters, Brussels
Vassilis Golfinopoulos (Clinical Research Physician) vassilis.golfinopoulos (at) eortc.org, EORTC Headquarters, Brussels
Thierry Gorlia (Statistician) thierry.gorlia (at) eortc.org, EORTC Headquarters, Brussels
Sara Meloen (Pharmacovigilance Manager) sara.meloen (at) eortc.org, EORTC Headquarters, Brussels
Sarah Nuyens (Clinical Operations Manager) sarah.nuyens (at) eortc.org, EORTC Headquarters, Brussels
Christine Olungu (Data Manager) christine.olungu (at) eortc.org, EORTC Headquarters, Brussels
Maureen Vanlancker (Clinical Research Physician) maureen.vanlancker (at) eortc.org, EORTC Headquarters, Brussels
Type of cancer Brain
Participating groups EORTC Brain Tumor Group
Recruiting centers Academisch Ziekenhuis Maastricht (Maastricht, Netherlands)
Assistance Publique - Hopitaux de Paris - Hopital Avicenne (Bobigny, France)
Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere (Paris, France)
CHRU de Lille (Lille, France)
CHU Dinant Godinne - UCL Namur (Yvoir, Belgium)
Cambridge University Hospital NHS - Addenbrookes Hospital (Cambridge, United Kingdom)
Catharina Ziekenhuis (Eindhoven, Netherlands)
Centre Hospitalier Universitaire Vaudois - Lausanne (Lausanne, Switzerland)
Centre Paul Strauss (Strasbourg, France)
Erasmus MC (Rotterdam, Netherlands)
Fondazione IRCCS Istituto Neurologico Carlo Besta (Milano, Italy)
Guy s and St Thomas' NHS - Guy's Hospital (London, United Kingdom)
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme (Brussels, Belgium)
Institut de Cancerologie de l’Ouest (ICO) - Centre Rene Gauducheau (Nantes - St. Herblain, France)
Institut régional du Cancer Montpellier (Montpellier, France)
Kepler University Hospital (Linz, Austria)
Klinikum Der J.W. Goethe Universitaet (Frankfurt Am Main, Germany)
Knappschaft Krankenhaus (Bochum-Langendreer, Germany)
Leeds Teaching Hospitals NHS Trust - St. James's University Hospital (Leeds, United Kingdom)
Medical University Vienna - General Hospital AKH (Vienna, Austria)
Medisch Centrum Haaglanden - Westeinde (Den Haag, Netherlands)
Nottingham University Hospitals NHS Trust - City Hospital (Nottingham, United Kingdom)
Ospedale Bellaria (Bologna, Italy)
St. Elisabethziekenhuis (Tilburg, Netherlands)
The Christie NHS Foundation Trust (Manchester, United Kingdom)
U.Z. Leuven - Campus Gasthuisberg (Leuven, Belgium)
UniversitaetsKlinikum Heidelberg - Head Hospital (Heidelberg, Germany)
UniversitaetsSpital Zurich (Zurich, Switzerland)
Universitaetsklinik Dusseldorf (Duesseldorf, Germany)
Universitaetskliniken Regensburg (Regensburg, Germany)
Universitaetsklinikum Bonn (Bonn, Germany)
Universitaetsklinikum Tuebingen- Crona Kliniken (Tuebingen, Germany)
Universitair Medisch Centrum - Academisch Ziekenhuis (Utrecht, Netherlands)
Universitair Ziekenhuis Antwerpen (Edegem, Belgium)
University Medical Center Groningen (Groningen, Netherlands)
Vrije Universiteit Medisch Centrum (Amsterdam, Netherlands)
Western General Hospital (Edinburgh, United Kingdom)
Centers to be activated CHU de Nancy - Hopital Central (Vandoeuvre-lès-Nancy, France)
Gustave Roussy (Villejuif, France)
Universitair Ziekenhuis Gent (Gent, Belgium)
University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre (Bristol, United Kingdom)
Protocol summary http://clinicaltrials.gov/ct/show/NCT01290939
NCT number NCT01290939
EudraCT 2010-023218-30